Matthew H Stenmark1, Jonathan B McHugh2, Matthew Schipper3, Heather M Walline4, Christine Komarck4, Felix Y Feng5, Francis P Worden6, Gregory T Wolf4, Douglas B Chepeha4, Mark E Prince4, Carol R Bradford4, Suresh K Mukherji7, Avraham Eisbruch5, Thomas E Carey4. 1. Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan. Electronic address: stenmark@med.umich.edu. 2. Department of Pathology, University of Michigan Medical Center, Ann Arbor, Michigan. 3. Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan; Department of Biostatistics, University of Michigan Medical Center, Ann Arbor, Michigan. 4. Department of Head and Neck Surgery, University of Michigan Medical Center, Ann Arbor, Michigan. 5. Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan. 6. Department of Medical Oncology, University of Michigan Medical Center, Ann Arbor, Michigan. 7. Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan.
Abstract
PURPOSE: To investigate the relationship between human papillomavirus (HPV) and Epstein-Barr virus (EBV) in nonendemic nasopharyngeal carcinoma (NPC) and assess the prognostic implications of viral status. METHODS AND MATERIALS: Paraffin-embedded tumor specimens from 62 patients with primary NPC diagnosed between 1985 and 2011 were analyzed for EBV and high-risk HPV. EBV status was determined by the use of in situ hybridization for EBV encoded RNA. HPV status was assessed with p16 immunohistochemistry and multiplex polymerase chain reaction MassArray for determination of HPV type. Proportional hazards models were used to compare the risk of death among patients as stratified by viral status. RESULTS: Of 61 evaluable tumors, 26 (43%) were EBV-positive/HPV-negative, 18 (30%) were HPV-positive/EBV-negative, and 17 (28%) were EBV/HPV-negative. EBV and HPV infection was mutually exclusive. HPV positivity was significantly correlated with World Health Organization grade 2 tumors, older age, and smoking (all P<.001). The racial distribution of the study population was 74% white, 15% African American, and 11% Asian/Middle Eastern. Among HPV-positive patients, 94% were white. At a median follow-up time of 7 years, HPV-positive and EBV/HPV-negative tumors exhibited worse outcomes than did EBV-positive tumors, including decreased overall survival (hazard ratio [HR] 2.98, P=.01; and HR 3.89, P=.002), progression-free survival (HR 2.55, P=.02; and HR 4.04, P<.001), and locoregional control (HR 4.01, P=.03; and HR 6.87, P=.001). CONCLUSION: In our Midwestern population, high-risk HPV infection may play an etiologic role in the development of nonendemic, EBV-negative NPC. Compared with EBV-positive NPC, HPV-positive and EBV/HPV-negative NPC are associated with worse outcomes. A larger confirmatory study is needed to validate these findings. Published by Elsevier Inc.
PURPOSE: To investigate the relationship between human papillomavirus (HPV) and Epstein-Barr virus (EBV) in nonendemic nasopharyngeal carcinoma (NPC) and assess the prognostic implications of viral status. METHODS AND MATERIALS: Paraffin-embedded tumor specimens from 62 patients with primary NPC diagnosed between 1985 and 2011 were analyzed for EBV and high-risk HPV. EBV status was determined by the use of in situ hybridization for EBV encoded RNA. HPV status was assessed with p16 immunohistochemistry and multiplex polymerase chain reaction MassArray for determination of HPV type. Proportional hazards models were used to compare the risk of death among patients as stratified by viral status. RESULTS: Of 61 evaluable tumors, 26 (43%) were EBV-positive/HPV-negative, 18 (30%) were HPV-positive/EBV-negative, and 17 (28%) were EBV/HPV-negative. EBV and HPV infection was mutually exclusive. HPV positivity was significantly correlated with World Health Organization grade 2 tumors, older age, and smoking (all P<.001). The racial distribution of the study population was 74% white, 15% African American, and 11% Asian/Middle Eastern. Among HPV-positive patients, 94% were white. At a median follow-up time of 7 years, HPV-positive and EBV/HPV-negative tumors exhibited worse outcomes than did EBV-positive tumors, including decreased overall survival (hazard ratio [HR] 2.98, P=.01; and HR 3.89, P=.002), progression-free survival (HR 2.55, P=.02; and HR 4.04, P<.001), and locoregional control (HR 4.01, P=.03; and HR 6.87, P=.001). CONCLUSION: In our Midwestern population, high-risk HPV infection may play an etiologic role in the development of nonendemic, EBV-negative NPC. Compared with EBV-positive NPC, HPV-positive and EBV/HPV-negative NPC are associated with worse outcomes. A larger confirmatory study is needed to validate these findings. Published by Elsevier Inc.
Authors: Jessica H Maxwell; Bhavna Kumar; Felix Y Feng; Francis P Worden; Julia S Lee; Avraham Eisbruch; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Theodoros N Teknos; Douglas B Chepeha; Jonathan B McHugh; Susan G Urba; Jay Stoerker; Heather M Walline; David M Kurnit; Kitrina G Cordell; Samantha J Davis; Preston D Ward; Carol R Bradford; Thomas E Carey Journal: Clin Cancer Res Date: 2010-02-09 Impact factor: 12.531
Authors: C H Rassekh; P L Rady; I Arany; S K Tyring; S Knudsen; K H Calhoun; H Seikaly; B J Bailey Journal: Laryngoscope Date: 1998-03 Impact factor: 3.325
Authors: Jessica H Maxwell; Bhavna Kumar; Felix Y Feng; Jonathan B McHugh; Kitrina G Cordell; Avraham Eisbruch; Francis P Worden; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Theodoros N Teknos; Douglas B Chepeha; Jay Stoerker; Heather Walline; Thomas E Carey; Carol R Bradford Journal: Head Neck Date: 2010-05 Impact factor: 3.147
Authors: A Giannoudis; M Ergazaki; J Segas; J Giotakis; G Adamopoulos; V Gorgoulis; D A Spandidos Journal: Cancer Lett Date: 1995-03-02 Impact factor: 8.679
Authors: Carole Fakhry; William H Westra; Steven J Wang; Annemieke van Zante; Yuehan Zhang; Eleni Rettig; Linda X Yin; William R Ryan; Patrick K Ha; Alicia Wentz; Wayne Koch; Jeremy D Richmon; David W Eisele; Gypsyamber D'Souza Journal: Cancer Date: 2017-02-27 Impact factor: 6.860
Authors: Hong Li; Sina J Torabi; Wendell G Yarbrough; Saral Mehra; Heather A Osborn; Benjamin Judson Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-06-01 Impact factor: 6.223
Authors: Eduardo Netto; Hugo Santos; Luís Carvalho; José Luis Capelo-Martínez; Miguel Rito; José Cabeçadas; Margarida Roldão Journal: Rep Pract Oncol Radiother Date: 2020-07-11
Authors: Adam Scheel; Emily Bellile; Jonathan B McHugh; Heather M Walline; Mark E Prince; Susan Urba; Gregory T Wolf; Avraham Eisbruch; Francis Worden; Thomas E Carey; Carol Bradford Journal: Laryngoscope Date: 2016-06-27 Impact factor: 3.325
Authors: Wen Jiang; Paul D Chamberlain; Adam S Garden; Betty Y S Kim; Dominic Ma; Emily J Lo; Diana Bell; G Brandon Gunn; Clifton D Fuller; David I Rosenthal; Beth M Beadle; Steven J Frank; William H Morrison; Adel K El-Naggar; Bonnie S Glisson; Erich M Sturgis; Jack Phan Journal: Head Neck Date: 2015-11-11 Impact factor: 3.147